Abstract: The perfluoroalkyl surfactant (PAS) of the general formula C.sub.x F.sub.2x+1 (CH.sub.2).sub.n S(CH.sub.2).sub.n,CO.sub.2 M wherein x is an integer of 3-8, each of n and n' is an interger of 2-4 and may be the same or different and M is hydrogen, an alkali metal or ammonium, provides an oral composition, such as a dentifrice or a mouthwash with effect in prevent plaque formation. A preferred PAS is Zonyl FSA, C.sub.3-8 F.sub.7-17 (CH.sub.2).sub.2 S(CH.sub.2).sub.2 COOLi.

Abstract: This invention relates to a novel chartreusin derivative of the general formula (I): ##STR1## and a salt thereof. This chartreusin derivative and a salt thereof have an excellent antitumor activity, which is exhibited even when the site of cancer inoculation and the site of drug administration are different. This invention further relates to a antitumorous composition containing the above-mentioned compound as active ingredient. This invention furthermore relates to a process for producing the above-mentioned chartreusin derivative or salt thereof.

Abstract: 5-Carbonate derivatives of milbemycins A.sub.3, A.sub.4 and A.sub.5 have valuable acaricidal, anthelmintic and other activities, especially against endo- and exoparasites.

Abstract: A method of enhancing the wound-healing process in animals utilizing glycyl-1-histidyl-1-lysine: copper(II) (GHL-Cu) is disclosed. GHL-Cu functions as a superoxide dismutase which detoxifies tissue-damaging oxygen radicals, but does not evoke an antigenic response. A method of treating inflammatory conditions in animals and a method of reducing the traumatic effects in animals occurring subsequent to major tissue damage utilizing GHL-Cu is also disclosed.

Abstract: A method that is direct and stereospecific is provided for the production of 2'-deoxyadenosine derivatives and related analogs. The method comprises glycosylation of the sodium salt of 2,6-dichloropurine or 6-chloropurine and ammonolysis of the glycosylate to obtain the corresponding 2-chloro-2'-deoxyadenosine or 2'-deoxyadenosine.

Abstract: Compounds including phloretin and/or phlorizin derivatives coupled to an undigestible and non-absorbable matrix are provided. The compounds have pharmacological efficacies. They inhibit sugar uptake from the intestine and may be used in composition form in methods for treating diabetes and for promoting weight loss. A method for the manufacture of these compounds and a novel intermediate phlorizin derivative for making these compounds are also disclosed.

Abstract: Disclosed is a process for purifying Factor VIII:C in high yield and potency from source material containing Factor VIII:C, Factor VIII:R and other plasma proteins and factors comprising the steps of: adsorbing Factor VIII:C onto a hydrophobic interaction matrix, separating unwanted proteins from Factor VIII:C and eluting Factor VIII:C by a solution containing a surface active agent.

Abstract: A 5-fluoro-2'-deoxyuridine derivative expressed by the following formula ##STR1## wherein R.sub.1 and R.sub.2 are the same or different from each other, each representing an alkyl group of 1 to 18 carbon atoms having a carboxyl group as a substituent, or an alkyl group of 9 to 14 carbon atoms, or its pharmacologically acceptable salt as the active ingredient.Said 5-fluoro-2'-deoxyuridine derivative displays a high-level antitumor effect in low doses and shows outstanding safety.

Abstract: A process for selectively controlling or interfering with the effect or function of foreign nucleic acid in the presence of otherwise normal living cells which comprises determining the base sequence for said nucleic acid and binding the said nucleic acid with an appropriately prepared nonionic oligonucleoside alkyl or arylphosphonate analogue which is complementary to the indicated sequence of the foreign nucleic acid.

Abstract: The present invention relates to a process for producing etoposide by reacting a 4'-halogenoacetyl-4'-demethylepipodophyllotoxin-.beta.-D-2,3-di-O-halogeno acetyl-4,6-O-ethylideneglucoside represented by the general formula: ##STR1## wherein R.sub.1 and R.sub.2, which may be the same or different, represent each --COCHX.sub.2 or --COCX.sub.3, wherein X represents a halogen atom, with an alcohol, an amine, and/or ammonia to remove the halogenoacetyl groups.

Abstract: A nutritonal fat suitable for enteral and parenteral products is disclosed. This fat consists essentially of from about 50 to 100% by weight triglycerides having the formula: ##STR1## wherein each R.sup.1 group is selected from n-heptanoyl, n-octanoyl, n-nonanoyl, n-decanoyl and n-undecanoyl groups; and the R.sup.2 groups comprise from 0 to about 90% saturated acyl groups selected from n-heptanoyl, n-octanoyl, n-nonanoyl, n-decanoyl, n-undecanoyl, lauroyl, myristoyl, palmitoyl, stearoyl and mixtures thereof; from 0 to about 90% oleoyl groups; from about 10 to 100% linoleoyl groups; and from 0 to about 10% linolenoyl groups.

Abstract: A flavone glycoside having the formula is isolated from the natural source and is found to be effective to amelioration of the hemolinetic disturbance.

Abstract: The invention relates to new alkyl ethers and phosphoric acid esters of Cassia tora polygalactomannans and their use, alone or in combination with other thickening agents, as thickening agents.

Abstract: A method of modulating immune responses in mammals by blocking immune complex binding to immunoglobulin Fc receptors is described, comprising administering a peptide comprising a portion selected from the amino acid sequence-Pro-Asp-Ala-Arg-His-Ser-Thr-Thr-Gln-Pro-Arg-Specific uses in reducing immune complex mediated inflammation or tissue destruction and in reducing the human allergic response are disclosed.

Abstract: A method of modulating immune complex mediated immune responses in mammals is described, comprising administering a peptide comprising the amino acid sequence-Thr-Ile-Ser-Lys-Ala-Lys-Gly-Gln-Pro-Arg-Specific uses in reducing immune complex mediated inflammation or tissue destruction and in modulating the proliferation or function of mononuclear cells are disclosed.

Abstract: A compound of the formula (I): ##STR1## in which: is a single bond or a double bond,X is hydrogen or hydroxy,n is 0 or 1,Z is ##STR2## when in ring B is a double bond, and, when in ring B is a single bond, Z is wherein W is hydrogen, lower acyl, unsubstituted arylcarbonyl, lower alkyl or substituted arylcarbonyl.These compounds are useful as platelet aggregation inhibitors.

Abstract: The invention relates to a process for increasing the sexual activity of birds and useful domestic mammals and for preparing spermatozoa suitable to their propagation. The process of the invention comprises treating sexually mature male birds or useful domestic mammals at least twice and at most four times with 0.1 to 5 .mu.g/kg of body weight of a compound of the general formula (I),Glp-His-Trp-Ser-Tyr-X.sub.1 -Leu-Arg-Pro-X.sub.4 (I)whereinX.sub.1 stands for a glycyl group, a natural or synthetic aminoacid or aminoacid derivative of D configuration, an -Asp-Q group of L configuration, wherein Q is attached to the .alpha.-carbonyl moiety of the aspartyl group and represents a C.sub.1-5 alkylamide, an arylamide, a C.sub.1-4 alkoxy or a benzyloxy group; andX.sub.4 stands for a glycylamide or a C.sub.1-4 alkylamide group,while keeping a pause of at least 30 hours and at most 72 hours between the consecutive treatments.

Abstract: 2'-Deoxy-2'-fluoro-.beta.-D-arabinofuranosyl nucleosides of the following structure are disclosed: ##STR1## wherein X and Y are the same or different and are hydrogen, OR.sup.3, SR.sup.3, NR.sup.3 R.sup.4 or NHacyl wherein R.sup.3 and R.sup.4 are the same or different and are hydrogen, lower alkyl of 1 to 7 carbon atoms, aralky, or aryl;NHacyl is alkanoyl or aroylamide;R.sup.1 and R.sup.2 are the same or different and are hydrogen, acyl or aroyl.

Abstract: Glycosylated plasminogen activator (t-PA) having a glycosylation pattern significantly different than exhibited by t-PA from Bowes melanoma cells is obtained from cultured normal human colon fibroblast cells (CCD-18Co).

Abstract: A method for the preparation of an N.sup.6 -substituted 3',5'-cyclic adenosine monophosphate or a salt thereof represented by the general formula ##STR1## wherein R.sub.1 represents a straight chain or branched chain alkyl group of 1 to 13 carbon atoms or an aromatic group and B.sym. represents a hydrogen ion or an alkali metal ion, which comprises allowing a 3',5'-cyclic adenosine monophosphate or a salt thereof represented by the general formula ##STR2## wherein A.sym. represents a hydrogen ion, alkali metal ion, organic ammonium ion, or ammonium ion, to react with an aldehyde represented by the general formulaR.sub.1 CHO (III)wherein R.sub.1 is as defined above, under the conditions such that pH is 7.0 or below, the temperature is -10.degree. to 120.degree. C., and the molar ratio of the compound (II) to the compound (III) is 1:1-40, and reducing the resulting compound with a metal hydride or nascent hydrogen.